133 related articles for article (PubMed ID: 38299685)
21. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
22. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS
Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540
[TBL] [Abstract][Full Text] [Related]
23. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
24. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
25. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia.
Jiang L; He Q; Chen X; Liu A; Ding W; Zhang H; Chen X; Zhou H; Meng Y; Liu B; Peng G; Wang C; Liu J; Shi X
Clin Transl Med; 2022 Sep; 12(9):e1038. PubMed ID: 36082692
[TBL] [Abstract][Full Text] [Related]
27. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
28. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Zhang WW; Cortes JE; Yao H; Zhang L; Reddy NG; Jabbour E; Kantarjian HM; Jones D
J Clin Oncol; 2009 Aug; 27(22):3642-9. PubMed ID: 19506164
[TBL] [Abstract][Full Text] [Related]
29. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
30. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract][Full Text] [Related]
31. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
32. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
34. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
Lu YH; Huang ZY
Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898
[TBL] [Abstract][Full Text] [Related]
35. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
36. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
38. miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Kotagama K; Chang Y; Mangone M
Drug Dev Res; 2015 Sep; 76(6):278-85. PubMed ID: 26284455
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA signature refine response prediction in CML.
Alves R; Gonçalves AC; Jorge J; Marques G; Luís D; Ribeiro AB; Freitas-Tavares P; Oliveiros B; Almeida AM; Sarmento-Ribeiro AB
Sci Rep; 2019 Jul; 9(1):9666. PubMed ID: 31273251
[TBL] [Abstract][Full Text] [Related]
40. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
